Nabiximols
Nabiximols
Nabiximols (pronunciation: na-bix-i-mols) is a patented cannabinoid oromucosal mouth spray developed by the UK company GW Pharmaceuticals. It is known in the trade as Sativex.
Etymology
The term "Nabiximols" is derived from the elements of its formulation: "Na" for sodium (a component of the spray), "bixi" for the bixin plant (from which the active ingredients are derived), and "mols" for molecules.
Pharmacology
Nabiximols is a complex botanical mixture containing equal proportions of tetrahydrocannabinol (THC) and cannabidiol (CBD), as well as other minor cannabinoids, terpenes, and flavonoids. The THC and CBD components are believed to contribute to the efficacy of Nabiximols in treating symptoms of multiple sclerosis and cancer pain.
Medical Uses
Nabiximols is used as a treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication. It is also used in the treatment of cancer pain, particularly in patients who have not responded to opioids.
Side Effects
Common side effects of Nabiximols include dizziness, fatigue, oral discomfort, dysgeusia, and nausea. More serious side effects may include hallucinations, delusions, and disorientation.
Legal Status
The legal status of Nabiximols varies by country. It is approved in many countries for the treatment of MS spasticity and in Canada for the treatment of cancer pain.
See Also
External links
- Medical encyclopedia article on Nabiximols
- Wikipedia's article - Nabiximols
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski